Melatonin induces autophagy via an mTOR-dependent pathway and enhances clearance of mutant-TGFBIp

Seung Il Choi, Kyu Seo Kim, Jun Young Oh, Jun Yup Jin, Ga Hyun Lee, Eungkweon Kim

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The hallmark of granular corneal dystrophy type 2 (GCD2) is the deposit of mutant transforming growth factor-β (TGF-β)-induced protein (TGFBIp) in the cornea. We have recently shown that there is a delay in autophagic degradation of mutant-TGFBIp via impaired autophagic flux in GCD2 corneal fibroblasts. We hypothesized that melatonin can specifically induce autophagy and consequently eliminate mutant-TGFBIp in GCD corneal fibroblasts. Our results show that melatonin activates autophagy in both wild-type (WT) and GCD2-homozygous (HO) corneal fibroblast cell lines via the mammalian target of rapamycin (mTOR)-dependent pathway. Melatonin treatment also led to increased levels of beclin 1, which is involved in autophagosome formation and maturation. Furthermore, melatonin significantly reduced the amounts of mutant- and WT-TGFBIp. Treatment with melatonin counteracted the autophagy-inhibitory effects of bafilomycin A1, a potent inhibitor of autophagic flux, demonstrating that melatonin enhances activation of autophagy and increases degradation of TGFBIp. Cotreatment with melatonin and rapamycin, an autophagy inducer, had an additive effect on mutant-TGFBIp clearance compared to treatment with either drug alone. Treatment with the selective melatonin receptor antagonist luzindole did not block melatonin-induced autophagy. Given its ability to activate autophagy, melatonin is a potential therapeutic agent for GCD2.

Original languageEnglish
Pages (from-to)361-372
Number of pages12
JournalJournal of Pineal Research
Volume54
Issue number4
DOIs
Publication statusPublished - 2013 May 1

Fingerprint

Autophagy
Melatonin
Sirolimus
Fibroblasts
Melatonin Receptors
Transforming Growth Factors
Cornea
Cell Line
Corneal dystrophy Avellino type

All Science Journal Classification (ASJC) codes

  • Endocrinology

Cite this

Choi, Seung Il ; Kim, Kyu Seo ; Oh, Jun Young ; Jin, Jun Yup ; Lee, Ga Hyun ; Kim, Eungkweon. / Melatonin induces autophagy via an mTOR-dependent pathway and enhances clearance of mutant-TGFBIp. In: Journal of Pineal Research. 2013 ; Vol. 54, No. 4. pp. 361-372.
@article{116a32b07f0342cc8edcbed2ca588f1a,
title = "Melatonin induces autophagy via an mTOR-dependent pathway and enhances clearance of mutant-TGFBIp",
abstract = "The hallmark of granular corneal dystrophy type 2 (GCD2) is the deposit of mutant transforming growth factor-β (TGF-β)-induced protein (TGFBIp) in the cornea. We have recently shown that there is a delay in autophagic degradation of mutant-TGFBIp via impaired autophagic flux in GCD2 corneal fibroblasts. We hypothesized that melatonin can specifically induce autophagy and consequently eliminate mutant-TGFBIp in GCD corneal fibroblasts. Our results show that melatonin activates autophagy in both wild-type (WT) and GCD2-homozygous (HO) corneal fibroblast cell lines via the mammalian target of rapamycin (mTOR)-dependent pathway. Melatonin treatment also led to increased levels of beclin 1, which is involved in autophagosome formation and maturation. Furthermore, melatonin significantly reduced the amounts of mutant- and WT-TGFBIp. Treatment with melatonin counteracted the autophagy-inhibitory effects of bafilomycin A1, a potent inhibitor of autophagic flux, demonstrating that melatonin enhances activation of autophagy and increases degradation of TGFBIp. Cotreatment with melatonin and rapamycin, an autophagy inducer, had an additive effect on mutant-TGFBIp clearance compared to treatment with either drug alone. Treatment with the selective melatonin receptor antagonist luzindole did not block melatonin-induced autophagy. Given its ability to activate autophagy, melatonin is a potential therapeutic agent for GCD2.",
author = "Choi, {Seung Il} and Kim, {Kyu Seo} and Oh, {Jun Young} and Jin, {Jun Yup} and Lee, {Ga Hyun} and Eungkweon Kim",
year = "2013",
month = "5",
day = "1",
doi = "10.1111/jpi.12039",
language = "English",
volume = "54",
pages = "361--372",
journal = "Journal of Pineal Research",
issn = "0742-3098",
publisher = "Wiley-Blackwell",
number = "4",

}

Melatonin induces autophagy via an mTOR-dependent pathway and enhances clearance of mutant-TGFBIp. / Choi, Seung Il; Kim, Kyu Seo; Oh, Jun Young; Jin, Jun Yup; Lee, Ga Hyun; Kim, Eungkweon.

In: Journal of Pineal Research, Vol. 54, No. 4, 01.05.2013, p. 361-372.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Melatonin induces autophagy via an mTOR-dependent pathway and enhances clearance of mutant-TGFBIp

AU - Choi, Seung Il

AU - Kim, Kyu Seo

AU - Oh, Jun Young

AU - Jin, Jun Yup

AU - Lee, Ga Hyun

AU - Kim, Eungkweon

PY - 2013/5/1

Y1 - 2013/5/1

N2 - The hallmark of granular corneal dystrophy type 2 (GCD2) is the deposit of mutant transforming growth factor-β (TGF-β)-induced protein (TGFBIp) in the cornea. We have recently shown that there is a delay in autophagic degradation of mutant-TGFBIp via impaired autophagic flux in GCD2 corneal fibroblasts. We hypothesized that melatonin can specifically induce autophagy and consequently eliminate mutant-TGFBIp in GCD corneal fibroblasts. Our results show that melatonin activates autophagy in both wild-type (WT) and GCD2-homozygous (HO) corneal fibroblast cell lines via the mammalian target of rapamycin (mTOR)-dependent pathway. Melatonin treatment also led to increased levels of beclin 1, which is involved in autophagosome formation and maturation. Furthermore, melatonin significantly reduced the amounts of mutant- and WT-TGFBIp. Treatment with melatonin counteracted the autophagy-inhibitory effects of bafilomycin A1, a potent inhibitor of autophagic flux, demonstrating that melatonin enhances activation of autophagy and increases degradation of TGFBIp. Cotreatment with melatonin and rapamycin, an autophagy inducer, had an additive effect on mutant-TGFBIp clearance compared to treatment with either drug alone. Treatment with the selective melatonin receptor antagonist luzindole did not block melatonin-induced autophagy. Given its ability to activate autophagy, melatonin is a potential therapeutic agent for GCD2.

AB - The hallmark of granular corneal dystrophy type 2 (GCD2) is the deposit of mutant transforming growth factor-β (TGF-β)-induced protein (TGFBIp) in the cornea. We have recently shown that there is a delay in autophagic degradation of mutant-TGFBIp via impaired autophagic flux in GCD2 corneal fibroblasts. We hypothesized that melatonin can specifically induce autophagy and consequently eliminate mutant-TGFBIp in GCD corneal fibroblasts. Our results show that melatonin activates autophagy in both wild-type (WT) and GCD2-homozygous (HO) corneal fibroblast cell lines via the mammalian target of rapamycin (mTOR)-dependent pathway. Melatonin treatment also led to increased levels of beclin 1, which is involved in autophagosome formation and maturation. Furthermore, melatonin significantly reduced the amounts of mutant- and WT-TGFBIp. Treatment with melatonin counteracted the autophagy-inhibitory effects of bafilomycin A1, a potent inhibitor of autophagic flux, demonstrating that melatonin enhances activation of autophagy and increases degradation of TGFBIp. Cotreatment with melatonin and rapamycin, an autophagy inducer, had an additive effect on mutant-TGFBIp clearance compared to treatment with either drug alone. Treatment with the selective melatonin receptor antagonist luzindole did not block melatonin-induced autophagy. Given its ability to activate autophagy, melatonin is a potential therapeutic agent for GCD2.

UR - http://www.scopus.com/inward/record.url?scp=84879464170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879464170&partnerID=8YFLogxK

U2 - 10.1111/jpi.12039

DO - 10.1111/jpi.12039

M3 - Article

C2 - 23363291

AN - SCOPUS:84879464170

VL - 54

SP - 361

EP - 372

JO - Journal of Pineal Research

JF - Journal of Pineal Research

SN - 0742-3098

IS - 4

ER -